# Perspective view of allogeneic IgG tumor immunotherapy

## TL;DR

This paper discusses how allogeneic IgG can trigger immune responses to fight tumors, offering a new perspective on immunotherapy.

## Contribution

The paper proposes new signaling pathways and mechanisms by which allogeneic IgG activates tumor eradication via dendritic cells.

## Key findings

- Allogeneic IgG combined with dendritic cell stimuli can eradicate tumors.
- AlloIgG triggers immune responses targeting multiple antigens.
- Only six articles have been published on this topic, indicating a need for more research.

## Abstract

Allogeneic tumors are eradicated by host immunity; however, it is unknown how it is initiated until the report in Nature by Yaron Carmi et al. in 2015. Currently, we know that allogeneic tumors are eradicated by allogeneic IgG via dendritic cells. AlloIgG combined with the dendritic cell stimuli tumor necrosis factor alpha and CD40L induced tumor eradication via the reported and our proposed potential signaling pathways. AlloIgG triggers systematic immune responses targeting multiple antigens, which is proposed to overcome current immunotherapy limitations. The promising perspectives of alloIgG immunotherapy would have advanced from mouse models to clinical trials; however, there are only 6 published articles thus far. Therefore, we hope this perspective view will provide an initiative to promote future discussion.